Effect of Chahel tablets in patients having Stress Issues.

An Open Label, Single arm Clinical Study to Evaluate the efficacy of Ambic Chahel Tablets in patients having Stress Issues - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/10/058410

Enrollment

Registered

2023-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F419- Anxiety disorder, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subject from 18-65 years of age. 2.Subject suffering from one or multiple mental health Issues from- anxiety, insomnia, depression etc; 3.Subjects that are able to give written informed consent in a manner approved by the institutional ethics committee and comply with the requirements of the study. 4.Subject willing to avoid participation in any other interventional clinical trial for the duration of the study.

Exclusion criteria

Exclusion criteria: 1.Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including oral or parenteral corticosteroids. 2.Subjects that have participated in any other interventional clinical trial in the previous 30 days. 3.Subjects with known sensitivity to any of the constituents of the investigational product.

Design outcomes

Primary

Measure	Time frame
Reduction in Stress Issues calculated as SGA Change in Cortisol level Change in EEG Assessment calculated as alpha, beta and thetaTimepoint: Time frame 0-30 days Time frame 0-30 days Time frame 0-30 days	—

Secondary

Measure	Time frame
Not applicableTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

Mittal Global Clinical Trial Services

puneetmittal@mgcts.org8937015757

Outcome results